Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Otis Worldwide Corp (OTIS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Otis Worldwide Corp — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while Otis Worldwide Corp trades at $72.17 (market cap $28.18B). The key difference: Otis Worldwide Corp is far larger — about 6.3× ACADIA Pharmaceuticals Inc.'s market cap, and Otis Worldwide Corp pays a 2.32% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | OTIS | |
|---|---|---|
Market Cap | $4.49B | $28.18B |
Sector | Health | Industrials |
52-Week High | $28.06 | $101.07 |
52-Week Low | $20.06 | $69.34 |
Enterprise Value | $3.69B | $35.56B |
Dividend Yield | — | 2.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
OTIS trades at $73.43, up 0.4% today, with a bullish technical signal and strong support at $72. The company reported $14.43B in 2025 revenue, a 10.11% net income margin, and a P/E of 19.55. Recent news highlights elevator modernization projects and a 5% dividend increase to $0.44 per share. Earnings have been mixed, with a Q1 2026 miss but service segment growth.
The stock offers a 28% upside to the $94 consensus price target, supported by buybacks and dividend growth, but faces risks from high debt and margin pressure. Analyst sentiment is mixed with 38% buy ratings. Execution on service growth and cost management is critical for re-rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Otis Worldwide Corp
Otis is the largest global elevator and escalator supplier by revenue with around one quarter of share excluding Japan. In 1854 Otis' founder and namesake, Elisha Graves Otis, invented a safety mechanism that prevented elevators from falling if the hoisting cable failed.The company's product and service lifecycle begins with installations of elevator units in new buildings, later selling maintenance services on the units, and eventually replacement of the units after the average 15-20 year useful life of an elevator. As the largest global OEM, over decades Otis has built a base of 2 million elevators under service. Its business model is much the same as that of its competitors Kone, Schindler, and Thyssenkrupp.
Read more on OTIS →
